导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.32% | 2574/4773 |
| 近一周 | -4.96% | 5182/5462 |
| 近一月 | -1.90% | 1080/5421 |
| 近一季 | -3.53% | 1426/5209 |
| 近半年 | -8.55% | 3365/4920 |
| 近一年 | 2.83% | 2043/4366 |
| 近两年 | 98.47% | 616/2954 |
| 近三年 | 61.09% | 430/2253 |
| 成立以来 | 256.88% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.43% 1277/4961 |
-1.30% 3346/5312 |
- - |
- - |
| 2025 | 40.23% 784/4813 |
8.25% 449/3635 |
8.96% 308/4076 |
13.88% 2964/4524 |
4.40% 533/4813 |
| 2024 | 7.45% 1656/3463 |
-11.42% 2432/2808 |
-11.00% 2488/3014 |
19.80% 808/3129 |
13.77% 133/3463 |
| 2023 | 33.27% 4/2656 |
21.80% 129/2280 |
6.48% 42/2385 |
-3.32% 897/2515 |
6.30% 26/2655 |
| 2022 | -5.99% 124/2207 |
-6.56% 221/1919 |
0.06% 1585/2016 |
-6.53% 105/2113 |
7.58% 299/2208 |
| 2021 | 35.08% 48/1822 |
-2.00% 570/1255 |
16.37% 206/1330 |
4.06% 384/1466 |
13.84% 71/1822 |
| 2020 | 17.16% 767/1250 |
1.81% 141/1028 |
8.61% 820/1067 |
13.40% 321/1164 |
-6.56% 1143/1184 |
| 2019 | 43.58% 189/1092 |
38.78% 57/739 |
-8.88% 616/788 |
1.74% 362/850 |
11.59% 53/918 |
| 2018 | -26.78% 400/834 |
- - |
-17.86% 587/631 |
-7.25% 441/660 |
-4.34% 27/682 |
| 2017 | -11.29% 542/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 大成360互联网+大数据100A VS. 长安沪深300非周期A(740101) |